Moderna (NASDAQ: MRNA)
Moderna Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Moderna Company Info
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA).
News & Analysis
Opinion: It's Time to Load Up on This Biotech Giant After Its 80% Crash
What Is Switching? What It Is, How It Works, & Example
2 Beaten-Down Stocks to Buy and Hold
Where Will Moderna Be in 10 Years?
Why Moderna Stock Was So Healthy This Week
Down 80%, Should You Buy the Dip on Moderna?
1 Beaten-Down Stock to Buy Right Now, and 1 to Avoid
Down 36%, Is Moderna a Buy on the Dip?
Valuation
Podcast Episodes
Microsoft's Gaming Ambitions and COVID-19 Stocks
Microsoft CEO Satya Nadella talked about his company's doubling down on gaming, which should give gamers and investors pause.
What Gives Moderna's Coronavirus Vaccine an Edge?
Moderna has got some promising news on the coronavirus vaccine front.
Why Moderna Stock Is Up
Moderna shares got a boost as the company continued its COVID-19 vaccine trials.
Why Moderna Stock Just Went Up
Encouraging news coming out of the biotech regarding its coronavirus vaccine candidate caused its stock to pop.
Earnings Transcripts
Moderna (MRNA) Q4 2024 Earnings Call Transcript
MRNA earnings call for the period ending December 31, 2024.
Moderna (MRNA) Q3 2024 Earnings Call Transcript
MRNA earnings call for the period ending September 30, 2024.
Moderna (MRNA) Q2 2024 Earnings Call Transcript
MRNA earnings call for the period ending June 30, 2024.
Moderna (MRNA) Q1 2024 Earnings Call Transcript
MRNA earnings call for the period ending March 31, 2024.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.